Breaking News
October 15, 2018 - Research reveals how the inner ear processes speech
October 15, 2018 - Many parents still skeptical about safety and effectiveness of flu shot, survey finds
October 15, 2018 - Payer Policies May Discourage Non-Pharma Tx for Low Back Pain
October 15, 2018 - Exercise may delay cognitive decline in people with rare Alzheimer’s disease
October 15, 2018 - Researchers modify CRISPR to reorganize genome | News Center
October 15, 2018 - Innovative brain tumor operation set to tailor to patients’ needs
October 15, 2018 - Findings offer new insight into early changes that occur during AD pathology
October 15, 2018 - Neurons regulating reproductive hormone release have different activity in epileptic mice
October 15, 2018 - More parents are concerned about taking babies swimming in public pools
October 15, 2018 - Health Tip: Know the Risk Factors for Lower Back Pain
October 15, 2018 - Study shows cigarillo flavors enhanced by high-intensity sweeteners
October 15, 2018 - Study traces hospital-acquired bloodstream infections to patients’ own bodies | News Center
October 15, 2018 - Abnormal vision in childhood can affect development of brain areas responsible for attention
October 15, 2018 - Color-changing contact lens could help doctors to monitor eye disease medications
October 15, 2018 - Tobacco heating products cause less staining to teeth than conventional cigarettes
October 15, 2018 - Young adults who are obese can expect to lose up to 10 years in life expectancy
October 15, 2018 - Scientists uncover how proteins meet on the cell membrane
October 15, 2018 - Affordable housing with supportive social services for senior citizens can reduce hospital use
October 15, 2018 - The latest ECG device from Schiller
October 15, 2018 - Following a Tissue Sample
October 15, 2018 - Prisoners need drug and alcohol treatments but AA programs aren’t the answer
October 15, 2018 - Andrea Califano and Jordan Orange Elected to National Academy of Medicine
October 15, 2018 - The impending risk of African Swine Fever Virus
October 15, 2018 - Breastfeeding reduces the number of antibiotic-resistant bacteria in infant gut
October 15, 2018 - Researchers develop comprehensive molecular atlas of postnatal mouse heart development
October 15, 2018 - ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting
October 15, 2018 - Engineering teratoma-derived fibroblasts to enhance osteogenesis
October 15, 2018 - Lab study shows effectiveness of potential therapy for treatment-resistant hypothyroidism
October 15, 2018 - JCU study firms up association between diet and depression
October 15, 2018 - Researchers to study the use of CRISPR on human liver on-a-chip platform
October 15, 2018 - Sub-concussive impacts not associated with decline in neurocognitive function
October 15, 2018 - Researchers find potential treatment to halt premature labor and birth
October 15, 2018 - As U.S. suicides rates rise, Hispanics show relative immunity
October 15, 2018 - FDA Issues a Complete Response Letter to Acacia Pharma for Barhemsys
October 15, 2018 - Photoactive bacteria bait may help in fight against MRSA infections
October 15, 2018 - Increasing vigorous exercise reduces risk factors of type 2 diabetes, cardiovascular disease in children
October 15, 2018 - First-of-its-kind study to test a personalized vaccine in cancer patient
October 15, 2018 - Extension trial assesses benefit of switching from flash monitoring to RT-CGM for hypoglycemia
October 15, 2018 - Half of parents say young children are afraid of doctor’s visits
October 15, 2018 - Study shows how fingerprint-based drug screening works on the living and deceased
October 15, 2018 - Study reveals potential to monitor progression of Alzheimer’s disease by measuring brain antioxidant levels
October 15, 2018 - FDA Approves Xarelto to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
October 15, 2018 - Promising new therapeutic approach against Ebola virus identified
October 15, 2018 - Study unravels how cancer stem cells use normal genes in abnormal ways
October 15, 2018 - Healthcare systems fail to deliver at affordable prices finds report
October 15, 2018 - Intensive BP Therapy in Diabetes May Lower Risk for CV Events
October 15, 2018 - Muscle relaxants increase risk of respiratory complications
October 15, 2018 - Female birds become more promiscuous after hatchings fail in the first breeding attempt
October 15, 2018 - Humans occupied Madagascar thousands of years later than previously thought
October 15, 2018 - Is Kidney Dialysis Always Needed When Septic Shock Strikes?
October 15, 2018 - Study shows invasive lung cancer surgery can lead to long-term opioid use
October 15, 2018 - Sugar, a “sweet” tool to understand brain injuries
October 14, 2018 - King’s commemorates activities and research on World Arthritis Day
October 14, 2018 - Humana and VFW NY team up on Stop 22 initiative to increase awareness of veterans committing suicide
October 14, 2018 - Water fluoridation contributes to urinary fluoride levels in pregnant women in Canada
October 14, 2018 - Study of children in Romanian orphanages tells cautionary tale about family separation
October 14, 2018 - Previous Endologix AFX Safety Notice classified by FDA as Class I recall
October 14, 2018 - Legal scholars sound alarm on academies’ report about returning research results to participants
October 14, 2018 - UNIST selects six extraordinary scholars to be induced as ‘Rising-star Distinguished Professor’
October 14, 2018 - Scientists find new way to help asthmatics breathe more easily
October 14, 2018 - New ‘gag rule’ may adversely impact health care of pregnant women
October 14, 2018 - Rosacea – Genetics Home Reference
October 14, 2018 - When the fighting crosses the line
October 14, 2018 - New findings could benefit patients with triple-negative breast cancer
October 14, 2018 - UK Biobank provides wealth of information for further genetic studies
October 14, 2018 - KHN’s ‘What the Health?’ Falling premiums and rising political tensions
October 14, 2018 - Duvelisib Promising for Chronic Lymphocytic Leukemia, SLL
October 14, 2018 - Tailored drug cocktails offer hope to kids with aggressive brain tumors
October 14, 2018 - Common gene variants linked to migraine risk in African-American children
October 14, 2018 - Funding requests are being accepted by BlueCross BlueShield of Tennessee Community Trust
October 14, 2018 - Using pulsed electric fields in cancer therapy
October 14, 2018 - Major Childbirth Complications More Likely for Black Women
October 14, 2018 - Young cancer survivors at greater risk of mental health disorders
October 14, 2018 - Common herbicide compound could help fight hospital-acquired fungal infections
October 14, 2018 - Alterations in genes encoding proteins contribute to ADHD development
October 14, 2018 - New patient-centric website launched in Europe to empower people with chronic conditions
October 14, 2018 - Antimicrobial signaling molecule has lower activity against hepatitis C virus in most humans
October 14, 2018 - Genomic dark matter activity connects Parkinson’s and psychiatric diseases
October 14, 2018 - Cornell dots equipped with antibody fragments offer a new cancer weapon
October 14, 2018 - Addressing social and cultural factors is key to reducing burden of type 2 diabetes
New ReFRAME drug repurposing collection offers hope for treating major diseases

New ReFRAME drug repurposing collection offers hope for treating major diseases

image_pdfDownload PDFimage_print

Each year, millions of people worldwide suffer from potentially fatal infectious diseases that often leave survivors facing a lifetime of related health problems. But what if drugs against such diseases already existed but nobody knew it?

Scientists at Calibr, a non-profit drug discovery division of Scripps Research, are now exploring that question using an extensive library they’ve built of nearly all existing small-molecule drugs shown to be appropriate for direct use in humans.

The Calibr scientists are using this collection, called ReFRAME, to identify existing drugs that show promise for treating major diseases. As a result of this ReFRAME initiative, two FDA-approved drugs are already being tested in clinical trials–one as a treatment for tuberculosis and another for the parasite Cryptosporidium spp., a major cause of severe diarrhea–within only a few short years of Calibr scientists discovering their utility. This is in contrast to the much longer timelines that often hinder new drug development.

Now, in another early success of the project and demonstration of its power to quickly find much needed novel therapies, the Calibr researchers used ReFRAME to identify two additional compounds that in preliminary testing appeared effective against Cryptosporidium spp. The results of the new Cryptosporidium study were reported this week in Proceedings of the National Academy of Sciences.

“ReFRAME takes the concept of accelerating impact on patients through repurposing existing drugs to a new level, offering great potential for finding much-needed therapies more quickly and cost-effectively,” says Pete Schultz, PhD, president and CEO of Scripps Research and Calibr, who is one of the lead researchers on the ReFRAME project. “The drugs we’ve assembled in ReFRAME have already been shown safe in humans, making them an incredibly valuable resource for tackling areas of urgent unmet medical need, especially neglected tropical diseases.”

To construct ReFRAME, Calibr researchers gathered data on more than 12,000 small-molecule drugs by combining three widely-used commercial drug databases (Clarivate Integrity, GVK Excelra GoStar and Citeline Pharmaprojects), which are typically used by pharmaceutical and biotech companies to assess competition and guide drug research and development. Calibr researchers also mined patent filings for drug candidates that had not yet reached these databases but that might hold potential as therapies for diseases outside their original therapeutic indications. With these data in hand, Calibr launched a massive campaign to obtain physical samples of all of the compounds, including purchase of about 7,000 compounds and de novo chemical synthesis of about 5,000 compounds, a project that involved around 500 chemists over an 18-month period. Sufficient quantities were generated to enable hundreds of laboratory tests over the coming years, both at Calibr, Scripps Research, and partner organizations around the globe.

“ReFRAME was developed as a singular new resource for the global health drug discovery community and is the largest and most comprehensive repurposing collection available,” says Arnab Chatterjee, PhD, vice president of medicinal chemistry at Calibr and lead researcher on the project. “In addition to consolidating compounds from multiple existing collections, we synthesized around 5,000 molecules that are not commercially available–from which we identified the two new hits against Cryptosporidium.”

Drugs that have been previously tested for safety in humans offer a major advantage over new compounds, as the time and cost of conducting preclinical trials in animals and early trials in humans represents a major hurdle to bringing new drugs to the clinic. Repurposing an existing drug can overcome these barriers, significantly lowering the cost and time required to develop a new way to prevent or treat a disease.

Repurposing drugs, however, is not as simple as it sounds. Prior to ReFRAME, information on existing drugs was spread across multiple databases. Similarly, there was no single, comprehensive source of samples of the actual drug compounds, so collecting thousands of compounds to test against any given disease was a significant logistical challenge. The Calibr team also synthesized close derivatives of many known drugs and included them in the collection, providing an important resource for screening multiple analogues of molecules for therapeutic applications.

“By combining three different commercial data sets and significant patent intelligence, we identified many unique compounds that have never been collected in one place,” says Jeff Janes, PhD, a principal investigator at Calibr and coauthor on the paper.

The first two drugs identified for potential repurposing using ReFRAME were the leprosy drug clofazimine and the arthritis drug auranofin. Calibr is collaborating with the University of Washington, who is sponsoring a Phase 2A clinical trial in Malawi, and the Bill and Melinda Gates Foundation to study the safety, tolerability, pharmacokinetics and efficacy of clofazimine in the treatment of cryptosporidiosis in HIV positive patients. Auranofin is currently being tested as a possible treatment for tuberculosis in a clinical trial taking place in South Africa.

In their new study, Calibr scientists used the institute’s high-throughput screening facility to test all 12,000 compounds against Cryptosporidium, a one-celled parasite that travels to the small intestine and bores into the intestine wall causing severe diarrhea.

Current approved treatment options for Cryptosporidium infection are limited to only one drug, nitazoxanide, which has modest potency and is ineffective in patients with compromised immune systems. Repurposing existing drugs was particularly appealing, as little drug discovery research targeting the parasite has taken place due to a lack of commercial interest developing drugs against the pathogen.

In their study, the Calibr scientists placed the parasites in thousands of small chambers and dosed them with samples of the drugs to determine which compounds killed them. Drugs that killed Cryptosporidium in the chambers were then given to mice infected with the parasite, and two drugs, VB-201(CI-201) and ASP-7962, proved effective at treating the infections in the animals. The researchers were able to move from identifying the compounds to animal studies in about two months, a remarkably rapid advance from one phase of drug discovery research to another.

“These two compounds show promise for providing therapeutics for targeting the parasite and not just the symptoms,” says Case McNamara, PhD, a principal investigator at Calibr and coauthor on the paper. “If they prove effective at treating this disease in humans, it could impact the lives of millions of people worldwide.”

The Calibr researchers plan to continue adding additional compounds to ReFRAME and are hoping to find drugs in the collection that can be repurposed as therapies to other infectious diseases that are widespread in the developing world. They have also developed an open-access data portal to share the results of their ReFRAME screening experiments with other researchers to encourage additional follow-up and maximize the impact of the screening collection.​

Source:

https://www.scripps.edu/news-and-events/press-room/2018/20181003-reframe-calibr.html

Tagged with:

About author

Related Articles